Clinical Trials Logo

Skin Diseases, Infectious clinical trials

View clinical trials related to Skin Diseases, Infectious.

Filter by:

NCT ID: NCT06247761 Not yet recruiting - Scar Clinical Trials

STASSH - TRAUMA - Absorbable vs Non-Absorbable Sutures in Trauma Hand Surgery

STASSH-TRAUMA
Start date: January 29, 2024
Phase: N/A
Study type: Interventional

An RCT will be set up to compare outcomes between two groups of hand surgery patients. These are: • Emergency hand surgery patients - randomized to either absorbable or non-absorbable suture. The primary outcomes investigated will be: • Infection occurrence The secondary outcomes will be: - Scar appearance at 1 week and 6-8 weeks (assessed from photographs and scar scoring scale) - Wound inflammation as a percentage of wound length at day 7 post surgery. - Patient symptoms at 1 week (assessed from patient questionnaire) - Patient symptoms at 6-8 weeks (assessed from patient questionnaire) - QDASH Score at 1 week (assessed from patient questionnaire) - QDASH score at 6-8 weeks (assessed from patient questionnaire) - Occurrence of other complications (assessed from the above photographs, the above questionnaires and from nurse and doctor led reports of wound breakdown and other complications)

NCT ID: NCT06170983 Not yet recruiting - Skin Infection Clinical Trials

Skin Inflammation and PK of Azithromycin

AZI_IMQ_LPS
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study will investigate the tissue distribution of azithromycin in healthy, artificially inflamed and actually infected tissue of humans.

NCT ID: NCT06149117 Completed - Clinical trials for Upper Respiratory Tract Infection

Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China

Start date: November 16, 2022
Phase: Phase 4
Study type: Interventional

Main research purpose To investigate the pharmacokinetics of the test preparation azithromycin capsule and the reference preparation azithromycin capsule (Sumamed®) in Chinese healthy adult subjects by single oral administration in fasting state, and to evaluate the bioequivalence of the two preparations by oral administration in fasting state. Secondary research purpose To investigate the safety of the test preparation azithromycin capsule and the reference preparation "Sumamed®" in healthy subjects.

NCT ID: NCT06087809 Completed - Clinical trials for Community-acquired Pneumonia

Improving Short Course Treatment for Common Pediatric Infections

Start date: February 15, 2023
Phase: N/A
Study type: Interventional

Randomized quality improvement trial to improve the proportion of cases of community-acquired pneumonia (CAP) treated with no more than 5 days of antibiotics the proportion of cases of skin and soft tissue infections (SSTI) treated with no more than 7 days of antibiotics by primary care clinicians (PCC) within the Pediatric Physicians' Organization at Children's (PPOC), a state-wide pediatric primary care network. Interventions include education and feedback; clinical decision support (CDS) delivered at the point of care; and the combination of the two.

NCT ID: NCT05899140 Not yet recruiting - Clinical trials for Staphylococcal Infections

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

SoTiClin
Start date: February 1, 2024
Phase: Phase 4
Study type: Interventional

This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.

NCT ID: NCT05828550 Not yet recruiting - Clinical trials for Patients withInfections Caused by S.Aureus Like Skin Infections , Chest Infections , Surgical Site Infections , and Urinary Tract Infections

Detection of Efflux Pump Genes Mediating Ciprofloxacin Resistance in Staphylococcus Aureus Isolates in Sohag University Hospitals

Start date: May 2023
Phase: N/A
Study type: Interventional

Among multidrug-resistant bacteria, Methicillin-resistant Staphylococcus aureus (MRSA) isolates were recognized to be an important mortality factor in hospital infections and a major concern in health-care and community settings . The antibiotic-resistant of S. aureus is extended by various bacterial strategies, including limiting uptake of the drug, alteration of the drugtargets, production of druginactivating enzymes and the activation of efflux pumps that effectively remove antibiotics . Relying on the type of antibiotics, bacteria can apply one or more strategies. Specifically, localization of resistance genes in transferable genetic elements, such as plasmid and transposons , causing Horizontal transfer of resistance genes between bacterial strains . MRSA strains are resistant to nearly all beta-lactam antibiotics by producing an alternative penicillin-binding protein known as PBP2a . This protein is encoded by the mecA gene and has a low affinity to manybeta-lactam antibiotics. Furthermore, these strains often show resistance to a wide range of antibiotics . The use of fluoroquinolone for the effective infectious therapy is limited by presence of fluoroquinolone resistance . There are two mechanisms causing resistance to fluoroquinolone. The first one is attributed to mutations occurring in the quinolone-resistance determining region (QRDR) of topoisomerase IV encoded by grlA/grlB and DNA gyrase encoded by gyrA/gyrB; these mutations decrease the affinity ofthe drug. The other mechanism is mediated by efflux pumps which is less recognized . Recently, several efflux pumps have been identified for S. aureus including efflux pumps encoded by chromosome or plasmids. The efflux pumps norA, norB, norC, mdeA, sepA, mepA, sdrM and lmrS are encoded by chromosome while qacA/B, qacG, qacH, qacJ and smr are plasmid-encoded . Efflux pumps could be specialized for specific substrate or mobilized a wide varieties of different antibiotic classes . Despite, efflux pumps can potentially increase resistance to antibiotics in clinical isolates of S. aureus, few studies have been evaluated the individual and collective participation of the efflux system in resistant isolates . Therefore the aim of the study is to detect ciprofloxacin resistant strains of staphylococcus aureus isolates and to detect efflux pump genes ( norA , norB and norC ) mediating resistance in such strains.

NCT ID: NCT05826873 Enrolling by invitation - Clinical trials for Urinary Tract Infections

Discharge Stewardship in Children's Hospitals

DISCO
Start date: June 10, 2020
Phase: N/A
Study type: Interventional

The goal of this interventional study is to test if a discharge stewardship bundle is effective at reducing inappropriate antibiotic prescriptions at hospital discharge for children with the three common infections: community-acquired pneumonia (CAP), urinary tract infections (UTI), and skin/soft tissue infections (SSTI). The goals of this study are: - To develop, locally adapt, and implement a discharge stewardship intervention across four geographically diverse children's hospitals. - To measure the impact of the discharge stewardship intervention on antibiotic prescribing and patient outcome for three common pediatric infections. Families who are enrolled in the study will be asked to: - complete a one question wellness track on days 3, 7, and 21 after hospital discharge - complete a brief survey on days 7 and 21 after hospital discharge The study team will conduct interviews with the hospitalists at each of the four participating hospitals to create a "discharge stewardship" bundle. Once the bundle intervention is implemented, the hospitalists will be asked to follow prescribing guidelines for CAP, UTI, and SSTI. They will receive regular group-level feedback reports to show how well they follow the guidelines and motivate the hospitalists to follow the guidelines better.

NCT ID: NCT05608382 Completed - Clinical trials for Skin Diseases, Infectious

Effect of an Antiseptic Solution on the Skin Microbiome

Start date: March 7, 2022
Phase: N/A
Study type: Interventional

The objective of this study is simulate the clinical use of an antiseptic solution in a 24 hour window and the recovery to baseline conditions at 1 month following application. Efficacy will be simulated as the capacity of the material to reduce or clear the skin bacterial population from a representative skin area: the anteromedial forearm.

NCT ID: NCT05339802 Recruiting - Skin Infection Clinical Trials

A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections

Start date: February 16, 2022
Phase: Phase 2
Study type: Interventional

In this study, a multicenter, randomized, double-blind, placebo-controlled trial design is used to evaluate the efficacy and safety of two doses of 9MW1411 injection in patients with ABSSSI caused by S. aureus. The Recommended Phase 2 Dose (RP2D) of 9MW1411 injection for this placebo-controlled study is comprehensively selected based on the results of Phase I clinical trials and preclinical PK/PD analysis. Approximately 90 subjects with ABSSSI caused by S. aureus are planned to be enrolled, and the infection type and presence or absence of single S. aureus infection will be used as randomization stratification factors for all randomized subjects. They are randomized in a 1: 1: 1 ratio.

NCT ID: NCT05226260 Active, not recruiting - Cellulitis Clinical Trials

Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care

SSTIBE
Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Study the efficacy of a package of behavioral economics strategies (versus an education-only control condition) in altering clinician behavior regarding antibiotic prescription duration for skin and soft tissue infection (SSTI).